Profiel
Greg Mann is currently working as the Media & Investor Relations Contact at Nkarta, Inc. He previously worked as the Director-Investor Relations at Abgenix, Inc., Executive Director-IR & Corporate Communications at FibroGen, Inc., and Vice President-Investor Relations at Kite Pharma, Inc.
Actieve functies van Greg Mann
| Bedrijven | Functie | Begin |
|---|---|---|
| NKARTA, INC. | Investor Relations Contact | 01-02-2020 |
Eerdere bekende functies van Greg Mann
| Bedrijven | Functie | Einde |
|---|---|---|
Abgenix, Inc.
 Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Investor Relations Contact | 01-01-2006 |
| KITE PHARMA INC | Investor Relations Contact | - |
| FIBROGEN, INC. | Investor Relations Contact | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
